Organization · Venture Capital
Vesalius Biocapital III
Vesalius Biocapital III is a European life sciences venture capital fund based in Luxembourg, focusing on later-stage investments in drug development, medical devices, diagnostics, and eHealth/mHealth sectors.
Overview
What Vesalius Biocapital III does
What Vesalius Biocapital III is
Vesalius Biocapital III is a European life sciences venture capital fund based in Luxembourg, focusing on later-stage investments in drug development, medical devices, diagnostics, and eHealth/mHealth sectors.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find Vesalius Biocapital III elsewhere
Open the official website or a supported primary organization account.
Capability profile
Vesalius Biocapital III as a funder
Investment thesis
Vesalius Biocapital III focuses on investing in young, innovative European life science companies at later stages of development, particularly in drug development, medical devices, diagnostics, and eHealth/mHealth. The fund emphasizes companies with validated clinical or commercial traction.
Focus narrative
Vesalius Biocapital III targets later-stage investments in European life science companies. The fund's strategy is centered on supporting companies that address unmet medical needs and possess strong intellectual property. Key sectors of interest include drug development, medical devices, diagnostics, and eHealth/mHealth.
Value beyond capital
Vesalius Biocapital III adds value to its portfolio companies by leveraging its team's deep technical and business expertise in the life sciences sector. The fund supports its companies in navigating clinical and commercial challenges, enhancing their growth potential and market reach.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Medical Devices · Digital Health
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 10
Portfolio context
Notable portfolio companies include: Memo Therapeutics AG: Developing antibodies for BK virus infections in renal transplant patients. SWORD Health: A tech-enabled provider of musculoskeletal care. Forendo Pharma: Focused on women's health, including treatments for endometriosis. CatalYm: Developing cancer immunotherapies. Topas Therapeutics: Working on immune tolerance therapies for autoimmune disorders.
Common questions
What to know about Vesalius Biocapital III
Upseed classifies Vesalius Biocapital III under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.